Published in J Biol Chem on February 28, 1997
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer (2003) 2.33
Functional characterization of Candida albicans ABC transporter Cdr1p. Eukaryot Cell (2003) 1.40
Optimized approaches for quantification of drug transporters in tissues and cells by MRM proteomics. AAPS J (2014) 1.03
Magneto-electric nanoparticles to enable field-controlled high-specificity drug delivery to eradicate ovarian cancer cells. Sci Rep (2013) 0.98
Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anticancer Agents (2004) 0.94
Effluxing ABC transporters in human corneal epithelium. J Pharm Sci (2010) 0.93
MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells. Br J Cancer (2000) 0.91
Influence of melanosome dynamics on melanoma drug sensitivity. J Natl Cancer Inst (2009) 0.86
Molecular analysis of the multidrug transporter, P-glycoprotein. Cytotechnology (1998) 0.85
Inhibition of uterine sarcoma cell growth through suppression of endogenous tyrosine kinase B signaling. PLoS One (2012) 0.81
Construction of a model cell line for the assay of MDR1 (multi drug resistance gene-1) substrates/inhibitors using HeLa cells. Pharmazie (2009) 0.78
Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol (1999) 2.43
Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood (2000) 2.39
Detection of cell-affecting agents with a silicon biosensor. Science (1989) 2.31
Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med (1992) 2.25
Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med (1999) 2.13
Rituximab in CD20 positive multiple myeloma. Leukemia (2007) 2.11
A therapy planning architecture that combines decision theory and artificial intelligence techniques. Comput Biomed Res (1987) 2.09
Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia (2001) 2.07
Factitious HIV infection: the importance of documenting infection. Ann Intern Med (1994) 2.05
Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol (1997) 1.86
Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis. J Biol Chem (1997) 1.84
Nutritional outcome and pneumonia in critical care patients randomized to gastric versus jejunal tube feedings. The Critical Care Research Team. Crit Care Med (1992) 1.81
Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol (1997) 1.77
Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis (1999) 1.75
Primary thyroid lymphoma is a heterogeneous disease. J Clin Endocrinol Metab (2002) 1.70
Subcellular localization, stoichiometry, and protein levels of 26 S proteasome subunits in yeast. J Biol Chem (1999) 1.69
Tubulin detyrosination is a frequent occurrence in breast cancers of poor prognosis. Cancer Res (2001) 1.67
Signalling sphingomyelinases: which, where, how and why? Biochim Biophys Acta (1999) 1.60
Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J Natl Cancer Inst (1995) 1.60
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol (1992) 1.49
Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res (1985) 1.43
Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia (2006) 1.42
Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res (1991) 1.39
Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol (2004) 1.37
Epidemiology of nosocomial pneumonia. New perspectives on an old disease. Chest (1995) 1.36
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol (2009) 1.33
Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma. Bone Marrow Transplant (2002) 1.33
Gastrin releasing peptide is a selective mitogen for small cell lung carcinoma in vitro. J Clin Invest (1985) 1.33
Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.32
HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med (1998) 1.30
Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood (1991) 1.29
Provider attitudes regarding participation of women and persons of color in AIDS clinical trials. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.29
Modulation by flavonoids of cell multidrug resistance mediated by P-glycoprotein and related ABC transporters. Cell Mol Life Sci (2002) 1.28
Modulation of multidrug resistance: at the threshold. J Clin Oncol (1993) 1.28
Signaling pathways activated by daunorubicin. Blood (2001) 1.28
Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. Mol Pharmacol (1999) 1.25
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol (1994) 1.25
Preventing nosocomial pneumonia: state of the art and perspectives for the 1990s. Am J Med (1991) 1.24
Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res (1996) 1.23
Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia (1998) 1.22
Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood (1997) 1.19
Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res (1994) 1.16
Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol (1980) 1.16
A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene (2007) 1.15
Multidrug resistance in lymphomas. J Clin Oncol (1994) 1.13
Nosocomial pneumonia in the 1990s: update of epidemiology and risk factors. Semin Respir Infect (1990) 1.12
Nosocomial pneumonia in mechanically ventilated adult patients: epidemiology and prevention in 1996. Semin Respir Infect (1996) 1.11
Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. Oncol Res (1995) 1.09
Expression of high Km 5'-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood (2001) 1.08
Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med (1983) 1.06
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol (1997) 1.06
Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am (1995) 1.06
Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer (1993) 1.05
Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia (1995) 1.04
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood (1999) 1.03
Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421. Leukemia (2012) 1.03
Development and characterization of a human sarcoma cell line, MES-SA, sensitive to multiple drugs. Cancer Res (1983) 1.02
Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol (1997) 1.02
Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep (1978) 1.02
CD40 signals apoptosis through FAN-regulated activation of the sphingomyelin-ceramide pathway. J Biol Chem (1999) 1.01
Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine. Ann Oncol (1997) 1.01
Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol (1992) 1.01
Pulmonary toxicity of antitumor agents. Cancer Treat Rev (1983) 1.00
Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem (2008) 1.00
Early diagnosis of ventilator-associated pneumonia. Is it possible to define a cutoff value of infected cells in BAL fluid? Chest (1996) 1.00
Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission. Cancer Res (1986) 0.99
High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol (2000) 0.97
Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. Br J Cancer (1999) 0.97
Doxorubicin induces slow ceramide accumulation and late apoptosis in cultured adult rat ventricular myocytes. Cardiovasc Res (1999) 0.96
Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res (1999) 0.96
Glucose metabolism in experimental hyperthyroidism: intact in vivo sensitivity to insulin with abnormal binding and increased glucose turnover. J Clin Endocrinol Metab (1984) 0.95
Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog. Science (1985) 0.95
Mutation rates and mechanisms of resistance to etoposide determined from fluctuation analysis. J Natl Cancer Inst (1994) 0.94
Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. Cancer Res (1992) 0.94
High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood (1998) 0.93
Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Cancer Chemother Pharmacol (1986) 0.92
Patterns of failure in small cell carcinoma of the lung. Cancer (1982) 0.92
Lysosomal sphingomyelinase is not solicited for apoptosis signaling. FASEB J (2000) 0.92
Factors that predict chemotherapy-induced myelosuppression in lymphoma patients: role of the tumor necrosis factor ligand-receptor system. J Clin Oncol (2000) 0.92
Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary. J Clin Oncol (1983) 0.92
Biochemical and cellular determinants of bleomycin cytotoxicity. Cancer Surv (1986) 0.91
Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the P-glycoprotein blocker PSC833. FASEB J (1998) 0.91
Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy (1993) 0.91
MDR 1 activation is the predominant resistance mechanism selected by vinblastine in MES-SA cells. Br J Cancer (2000) 0.91
Quantification of bleomycin pulmonary toxicity in mice by changes in lung hydroxyproline content and morphometric histopathology. Cancer Res (1978) 0.91
Response of lymphoepithelial parotid cysts to antiretroviral treatment in HIV-infected adults. Ann Intern Med (1998) 0.90
Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines. Int J Cancer (1994) 0.90
Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l'Artérite à Cellules Géantes. Ann Rheum Dis (1999) 0.90
Cell surface-directed interaction of anthracyclines leads to cytotoxicity and nuclear factor kappaB activation but not apoptosis signaling. Cancer Res (2001) 0.89
Synovial cyst of the hip causing iliac vein and femoral nerve compression. Clin Exp Rheumatol (1987) 0.89